{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:34:43Z","timestamp":1769834083567,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Routine human papillomavirus (HPV) vaccination in the US is recommended at ages 11 or 12 years and can be given at age 9. Vaccination completion rates among adolescents 13\u201315 years in the US remain below the 80% goal. This study evaluated the long-term effects of increasing proactive HPV vaccination initiation rates at age 9\u2009years in completion rates of adolescents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An age-structured vaccination model was developed and parametrized based on the National Immunization Survey-Teen (NIS-Teen) survey data. The model projected vaccination coverage (by vaccination status and age group), for 20 years, for a <jats:italic>routine initiation<\/jats:italic> scenario (no increase in initiation rates of 9-year-olds) and different <jats:italic>proactive initiation<\/jats:italic> (increased age 9 initiation) scenarios. The time to reach a completion rate of 80% for 13\u201315-year-olds was estimated. The model also generated projections stratified for subgroups of interest.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Results indicated that vaccine completion rates of 80% in 13\u201315-year-olds may not be achieved by 2040 under current trends of routine initiation at ages 11 or 12 years. However, increasing initiation rates in 9-year-olds by 1% and 3% annually could shorten the time to achieve 80% completion by 4 and 8 years, respectively. Stratification analyses showed that increasing initiation rates in 9-year-olds can also reduce disparities across subgroups in the time to achieve vaccination completion targets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Increasing HPV vaccination initiation rates in 9-year-olds by as little as 1%\u20133% annually may be an effective strategy to improve HPV vaccination completion rates in adolescents by age 15 and reach the Healthy People goal of 80% completion much earlier.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1393897","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T14:45:04Z","timestamp":1719499504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13\u201315 in the US: projections from an age-structured vaccination model"],"prefix":"10.3389","volume":"12","author":[{"given":"Kunal","family":"Saxena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Patterson-Lomba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Gomez-Lievano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Zion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Cunningham-Erves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Kepka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"B1","first-page":"620","article-title":"Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014\u2014United States","volume":"63","author":"Stokley","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"912","DOI":"10.15585\/mmwr.mm7234a3","article-title":"Vaccination coverage among adolescents aged 13\u201317 years \u2014 national immunization survey\u2013teen, United States, 2022","volume":"72","author":"Pingali","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1080\/03007995.2021.1981842","article-title":"Impact of the COVID-19 pandemic on adolescent vaccinations: projected time to reverse deficits in routine adolescent vaccination in the United States","volume":"37","author":"Saxena","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B4","article-title":"Ann-Christine Nyquist. Why AAP recommends initiating HPV vaccination as early as age 9","author":"O\u2019Leary","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2136444","DOI":"10.1080\/21645515.2022.2136444","article-title":"An opportunity to increase human papillomavirus vaccination rates: change the guidelines","volume":"18","author":"Aragones","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2022058794","DOI":"10.1542\/peds.2022-058794","article-title":"Early initiation of HPV vaccination and series completion in early and mid-adolescence","volume":"151","author":"Goodman","year":"2023","journal-title":"Pediatrics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2146434","DOI":"10.1080\/21645515.2022.2146434","article-title":"Why the American Academy of Pediatrics recommends initiating HPV vaccine at age 9","volume":"18","author":"O\u2019Leary","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2161253","DOI":"10.1080\/21645515.2022.2161253","article-title":"HPV Vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US","volume":"19","author":"Saxena","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2180971","DOI":"10.1080\/21645515.2023.2180971","article-title":"Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?","volume":"19","author":"O\u2019Leary","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2175555","DOI":"10.1080\/21645515.2023.2175555","article-title":"The association of initiating HPV vaccination at ages 9\u201310 years and up-to-date status among adolescents ages 13\u201317 years, 2016\u20132020","volume":"19","author":"Minihan","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2172276","DOI":"10.1080\/21645515.2023.2172276","article-title":"Framing of national HPV vaccine recommendations and willingness to recommend at ages 9\u201310","volume":"19","author":"Kahn","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/LGT.0000000000000648","article-title":"Long-term multilevel intervention impact on human papillomavirus vaccination rates spanning the COVID-19 pandemic","volume":"26","author":"Casey","year":"2022","journal-title":"J Low Genit Tract Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ypmed.2016.02.039","article-title":"Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion","volume":"89","author":"Sauver JL","year":"2016","journal-title":"Prev Med"},{"key":"B14","first-page":"1","article-title":"Youth risk behavior surveillance\u2014united States, 2011","volume":"61","author":"Eaton","year":"2012","journal-title":"MMWR Surveill Summ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2178219","DOI":"10.1080\/21645515.2023.2178219","article-title":"Recommending HPV vaccination at age 9 to reduce health disparities: communication challenges and opportunities","author":"Coyne-Beasley","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jpeds.2019.10.025","article-title":"Provider experience recommending HPV vaccination before age 11 years","volume":"217","author":"Biancarelli","year":"2020","journal-title":"J Pediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.acap.2022.01.008","article-title":"Recommending human papillomavirus vaccination at age 9: a national survey of primary care professionals","author":"Kong","year":"2022","journal-title":"Acad Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3322\/caac.21616","article-title":"Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation","volume":"70","author":"Saslow","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B19","article-title":"Immunizations for adolescents (IMA)","year":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-11664-1","article-title":"HPV Vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States","volume":"21","author":"Prabhu","year":"2021","journal-title":"BMC Public Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.569500","article-title":"On the use of markov models in pharmacoeconomics: pros and cons and implications for policy makers","volume":"703","author":"Carta","year":"2020","journal-title":"Front Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2165\/00019053-200826020-00004","article-title":"Modelling methods for pharmacoeconomics and health technology assessment","volume":"26","author":"Stahl","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"B24","volume-title":"National Center for Immunization and Respiratory Diseases. the 2022 National Immunization Survey\u2014teen","year":"2023"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1016\/j.vaccine.2022.09.073","article-title":"Trends in HPV vaccine administration and HPV vaccine coverage in children by race\/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California","volume":"40","author":"Chao","year":"2022","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1158\/1055-9965.EPI-19-1103","article-title":"Patterns and disparities in human papillomavirus (HPV) vaccine uptake for young female adolescents among US states: NIS-teen (2008\u20132016) patterns and disparities in HPV vaccine uptake","volume":"29","author":"Yoo","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1016\/j.vaccine.2024.03.050","article-title":"Effect of age at initiation of the human papillomavirus vaccine on the association between race\/ethnicity and completion of the vaccine series","volume":"42","author":"Hirth","year":"2024","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.32614\/RJ-2017-036","article-title":"Discrete time markov chains with R","volume":"9","author":"Spedicato","year":"2017","journal-title":"R J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3978\/j.issn.2223-4683.2014.11.02","article-title":"Pros, cons, and ethics of HPV vaccine in teens\u2014why such controversy?","volume":"3","author":"White","year":"2014","journal-title":"Transl Androl Urol"},{"key":"B30","first-page":"211","article-title":"Human papillomavirus vaccine hesitancy in the United States","volume":"70","author":"Morales-Campos","year":"2023","journal-title":"Pediatric Clinics"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1393897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T14:45:19Z","timestamp":1719499519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1393897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":30,"alternative-id":["10.3389\/fped.2024.1393897"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1393897","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"article-number":"1393897"}}